Study title: von Minckwitz GRa, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. Journal of Clinical Oncology~ 19(15):3506-3515, August 1, 2001 2001;(15):-3515, August.von Minckwitz GRa, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. Journal of Clinical Oncology~ 19(15):3506-3515, August 1, 2001 2001;(15):-3515, August.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: TAMOXIFEN | |||||
| ATC code: L02BA01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |